S&P 500   5,123.41
DOW   37,983.24
QQQ   441.72
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Wall Street gains ahead of earnings, oil falls as Middle East tensions escalate
Citi’s Results Say This About The Stock Market
Did You Miss the Gold Rush? Try These 2 Silver Stocks
S&P 500   5,123.41
DOW   37,983.24
QQQ   441.72
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Wall Street gains ahead of earnings, oil falls as Middle East tensions escalate
Citi’s Results Say This About The Stock Market
Did You Miss the Gold Rush? Try These 2 Silver Stocks
S&P 500   5,123.41
DOW   37,983.24
QQQ   441.72
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Wall Street gains ahead of earnings, oil falls as Middle East tensions escalate
Citi’s Results Say This About The Stock Market
Did You Miss the Gold Rush? Try These 2 Silver Stocks
S&P 500   5,123.41
DOW   37,983.24
QQQ   441.72
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Wall Street gains ahead of earnings, oil falls as Middle East tensions escalate
Citi’s Results Say This About The Stock Market
Did You Miss the Gold Rush? Try These 2 Silver Stocks
NASDAQ:CBAY

CymaBay Therapeutics (CBAY) Stock Price, News & Analysis

$32.48
+0.01 (+0.03%)
(As of 03/22/2024)
Today's Range
$32.48
$32.50
50-Day Range
$23.86
$32.48
52-Week Range
$7.26
$32.50
Volume
8.36 million shs
Average Volume
4.11 million shs
Market Capitalization
$3.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.65

CymaBay Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.08 Rating Score
Upside/​Downside
11.8% Downside
$28.65 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.00mentions of CymaBay Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$981,119 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.38) to ($1.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.95 out of 5 stars

Medical Sector

295th out of 928 stocks

Pharmaceutical Preparations Industry

125th out of 426 stocks

CBAY stock logo

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

CBAY Stock Price History

CBAY Stock News Headlines

My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
Gilead Sciences Completes Acquisition Of CymaBay Therapeutics
CBAY Jul 2024 34.000 call
CBAY Apr 2024 31.000 put
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
CBAY Oct 2024 33.000 call
CBAY Oct 2024 29.000 put
Maintaining Hold on CymaBay Amid Gilead Acquisition Deal Closure
CymaBay Therapeutics 4Q Loss/Shr 35c >CBAY
CBAY Jan 2026 37.000 call
CBAY Feb 2024 33.000 call
CBAY Jan 2025 8.000 put
See More Headlines
Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/15/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CBAY
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.65
High Stock Price Target
$32.50
Low Stock Price Target
$15.00
Potential Upside/Downside
-11.8%
Consensus Rating
Hold
Rating Score (0-4)
2.08
Research Coverage
12 Analysts

Profitability

Net Income
$-105,370,000.00
Pretax Margin
-339.11%

Debt

Sales & Book Value

Annual Sales
$31.07 million
Book Value
$2.58 per share

Miscellaneous

Free Float
106,693,000
Market Cap
$3.73 billion
Optionable
Optionable
Beta
0.32
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives


CBAY Stock Analysis - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CBAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CBAY, but not buy additional shares or sell existing shares.
View CBAY analyst ratings
or view top-rated stocks.

What is CymaBay Therapeutics' stock price target for 2024?

12 brokers have issued 12-month target prices for CymaBay Therapeutics' shares. Their CBAY share price targets range from $15.00 to $32.50. On average, they anticipate the company's share price to reach $28.65 in the next twelve months. This suggests that the stock has a possible downside of 11.8%.
View analysts price targets for CBAY
or view top-rated stocks among Wall Street analysts.

How have CBAY shares performed in 2024?

CymaBay Therapeutics' stock was trading at $23.62 on January 1st, 2024. Since then, CBAY stock has increased by 37.5% and is now trading at $32.48.
View the best growth stocks for 2024 here
.

When is CymaBay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CBAY earnings forecast
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) released its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.42 million.

What ETFs hold CymaBay Therapeutics' stock?

ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CBAY) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners